乌鸦传媒視頻

Data support that ICI rechallenge should be discouraged in patients with advanced RCC

News, features, and commentary about cancer-related issues

See the breakdown of this physician's weekly budget, from eating out to sailing lessons

Incidence almost identical to that with standard cancer treatment in randomized trials

Objective response rate was 55% with 12-mg/kg ifinatamab deruxtecan

"This is sort of the dirty underbelly of the current healthcare environment," an oncologist said

However, plinabulin plus docetaxel still "not ready for prime time," expert says

Absolute improvement of almost 30%, doubling of duration of response with savolitinib

Toxins are embedded in the soil, but no one can say what has caused such widespread illness

Two-trial analysis shows about a 40% decreased risk of disease recurrence or death

For patients with vaso-occlusive episodes, lactated Ringer was better than normal saline

Novel agent nearly halved risk of progression as first-line therapy in phase III trial

Princess of Wales says she will return to some public duties

Add-on ADC, monoclonal antibody consistently increase pCR versus PD-1 inhibitor plus chemotherapy